Strengthening the Potential of Genetic Diagnoses: A Conversation With Drs. Lucy Godley and Jorge Di Paola
Dr. Laura Michaelis interviews Drs. Lucy Godley and Jorge Di Paola about the work their expert panels are doing with ClinGen.
Does Renal Function Deteriorate in Individuals With Sickle Cell Trait and Sickle Cell Disease? Now We Know
Dr. Saah and Dr. Osunkwo study renal function in individuals with sickle cell trait and sickle cell disease.
Dr. Raje and Dr. Yee look at the RVD regimen (lenalidomide, bortezomib, and dexamethasone) as standard of care in newly diagnosed multiple myeloma.
Dr. Raje and Dr. Yee cover efforts to identify new pathways to treat multiple myeloma relapse.
Dr. Raje and Dr. Yee covers the DETERMINATION trial, which will provide greater clarity on how long to use maintenance lenalidomide and whether longer maintenance will narrow the gap in PFS between upfront and deferred transplant approaches.
Drs. Raje, Yee, and Lohr discuss the development of a new tool for exploring the complexity of multiple myeloma through circulating myeloma cells, which could replace bone marrow biopsies and permits analysis to be performed at multiple time points.
Dr. Raje, Dr. Yee and Dr. O'Donnell discuss various daratumumab combinations that have emerged as options for the treatment of multiple myeloma.
Dr. Raje and Dr. Yee discuss a study that looks at the use of pembrolizumab in combination with lenalidomide or pomalidomide to treat multiple myeloma as a form of checkpoint inhibition, a new important tool in cancer treatment.
Drs. Raje, O'Donnell, and Yee discuss progress in drugs for the treatment of multiple myeloma, especially immuno-oncology and monoclonal antibodies (MoABs).
Drs. Raje and Yee discuss two trials with elotuzumab and daratumumab that use monoclonal antibodies in the treatment of multiple myeloma.
Dr. Raje and Dr. Yee discuss the need for new agents in the therapy or treatment of patients with multiple myeloma, taking into account the FDA approval of penobinostat, and a study that looks at HDAC inhibition.
Dr. Yee and Dr. Raje review several trials to explain new courses of treatment for multiple myeloma, specifically an oral, active, well-tolerated PI.
March-April 2020Volume 17, Issue 2
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology